DataExpo GAKG DeepReport Navigation

Copyright©2015-2024 Acemap, Inc. Shanghai Jiao Tong University. All rights reserved.

沪ICP备18028330号

KS

K. Shitara

National Cancer Center Hospital East

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

T. Yoshino

National Cancer Center Hospital East

Y. Nakamura

National Cancer Center Hospital East

E. Oki

Kyushu University

T. Yoshino

National Cancer Center Hospital East

M. Shiozawa

Kanagawa Prefectural Hospital Organization

M. Saori

A. Ochiai

Tokyo University of Science

Naohiro Okano

Kyorin University

S. SATO

Gunma University

Nozomu Machida

Kanagawa Prefectural Hospital Organization

Cooperative Institutions

National Cancer Center Hospital East

Shizuoka Cancer Center

Yokohama City University

Chiba Cancer Center

Kyorin University

The University of Tokyo

Kanagawa Prefectural Hospital Organization

Kanagawa Cancer Center

Aichi Cancer Center

Japanese Foundation For Cancer Research

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

323P Five-year efficacy and safety in a randomized phase III trial investigating duration of adjuvant oxaliplatin-based therapy (3- vs. 6-months) for patients with high-risk stage II colon cancer: ACHIEVE-2 trial

Annals of Oncology (2022)

A. Makiyama K. Yamazaki M. Shiozawa D. Manaka M. Kotaka

Adjuvant Therapy

10.1016/j.annonc.2022.07.461

Cite

Citations (0)

1420P Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)

Annals of Oncology (2024)

S. SATO Shannon Rhodes Yu Aoki I. Nakayama Takuya HASHIMOTO

10.1016/j.annonc.2024.08.1486

Cite

Citations (1)

The immunotherapy challenge in locally advanced gastroesophageal cancer: VESTIGE trial’s insights and future pathways

Annals of Oncology (2024)

Izuma Nakayama Y. Nakamura K. Shitara

Cancer Immunotherapy

10.1016/j.annonc.2024.11.004

Cite

Citations (0)

LBA O-10 First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results

Annals of Oncology (2022)

K. Muro J. Watanabe K. Shitara K. Yamazaki H. Ohori

Panitumumab

Clinical endpoint

Progression-free survival

10.1016/j.annonc.2022.04.454

Cite

Citations (2)

120P Uncovering the prognostic potential of FGFR2c isoform expression in advanced gastroesophageal cancer through MONSTAR-SCREEN-2 analysis

ESMO Open (2024)

Tadayoshi Hashimoto Naoko Iida Shigenori Kadowaki Akitaka Makiyama Nozomu Machida

Expression (computer science)

10.1016/j.esmoop.2024.103859

Cite

Citations (0)